High-dimensional deconstruction of ovarian cancer at single-cell precision reveals HEBP2 that reshape the TIME and drive carboplatin resistance

High-dimensional deconstruction of ovarian cancer at single-cell precision reveals HEBP2 that reshape the TIME and drive carboplatin resistance

Background: Single-cell sequencing was employed to analyze the tumor immune microenvironment in ovarian cancer (OC) patients, exploring the evolutionary roles of various macrophage subgroups in OC progression and their correlation with fatty acid metabolism-related genes in contributing to drug resi...

Full description

Bibliographic Details
Main Authors:	BiKang Yang, Miao Dai
Format:	Article
Language:	English
Published:	Elsevier 2024-06-01
Series:	Translational Oncology
Subjects:	Single-cell Ovarian cancer Drug resistance HEBP2 Macrophage
Online Access:	http://www.sciencedirect.com/science/article/pii/S1936523324000421

Similar Items

Evaluation and comparison of the apical seal obtained with Biodentine after conditioning of root end with three different solutions using ultraviolet-visible spectrophotometer: An in vitro study
by: Sethuparvathi Anitha, et al.
Published: (2021-01-01)

Increased expression of heme-binding protein 1 early in Alzheimer's disease is linked to neurotoxicity
by: Oleksandr Yagensky, et al.
Published: (2019-08-01)

Heme Interactions as Regulators of the Alternative Pathway Complement Responses and Implications for Heme-Associated Pathologies
by: Stefanos A. Tsiftsoglou
Published: (2023-06-01)

Continuous Chelation Concept in Endodontics
by: Ayat H Adham, et al.
Published: (2022-12-01)

Effect of various final irrigation solutions at different temperatures on dentin tubule penetration of bioceramic-based root canal sealer
by: Esra Arılı Öztürk, et al.
Published: (2025-03-01)

Association between genetically plasma proteins and osteonecrosis: a proteome-wide Mendelian randomization analysis
by: Chen Meng, et al.
Published: (2024-07-01)

Does the addition of metformin to carboplatin treatment decreases ovarian reserve damage associated with carboplatin usage?
by: Sevgi Ayhan, et al.
Published: (2023-09-01)

Single-cell transcriptome analysis of macrophage subpopulations contributing to chemotherapy resistance in ovarian cancer
by: Xiaolin Zhong, et al.
Published: (2024-09-01)

Dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin treatment for stage II-IV ovarian cancer patients
by: Zhenhua Du, et al.
Published: (2015-07-01)

New insight into the role of macrophages in ovarian function and ovarian aging
by: Maoxing Tang, et al.
Published: (2023-11-01)

Retrospective Analysis Of Comparative Outcomes In Recurrent Platinum-Sensitive Ovarian Cancer Treated With Pegylated Liposomal Doxorubicin (Lipo-Dox) And Carboplatin Versus Paclitaxel And Carboplatin
by: Weng CS, et al.
Published: (2019-11-01)

Limitations to the use of carboplatin-based therapy in advanced ovarian cancer
by: Christina Fotopoulou
Published: (2014-12-01)

Unilateral Optic Disc Papilloedema following Administration of Carboplatin Chemotherapy for Ovarian Carcinoma
by: Philippa Lewis, et al.
Published: (2014-01-01)

C5aR1 blockade reshapes immunosuppressive tumor microenvironment and synergizes with immune checkpoint blockade therapy in high-grade serous ovarian cancer
by: Chen Zhang, et al.
Published: (2023-12-01)

Chito-oligosaccharides and macrophages have synergistic effects on improving ovarian stem cells function by regulating inflammatory factors
by: K. Zheng, et al.
Published: (2023-04-01)

Effects of paclitaxel combined with carboplatin on expression of VEGF and tumor markers in ovarian cancer
by: TAN Shufen, YANG Xielan, YANG Linlin, LI Shuqing
Published: (2023-12-01)

Comparison of Neoadjuvant Chemotherapy Efficiency in Advanced Ovarian Cancer Patients Treated With Paclitaxel Plus Carboplatin and Intraperitoneal Bevacizumab vs. Paclitaxel With Carboplatin
by: Yin Tao, et al.
Published: (2022-03-01)

Opposite Macrophage Polarization in Different Subsets of Ovarian Cancer: Observation from a Pilot Study
by: Ann Vankerckhoven, et al.
Published: (2020-01-01)

Investigation of Characteristics and Behavior of Loaded Carboplatin on the, Liposomes Nanoparticles, on the Lung and Ovarian Cancer: An In-Vitro Evaluation
by: Majid Hasanzadegan Roudsari, et al.
Published: (2016-04-01)

Effective sequential combined therapy with carboplatin and a CDC7 inhibitor in ovarian cancer
by: Junping Li, et al.
Published: (2024-01-01)

Up-regulation of GSTT1 in serous ovarian cancer associated with resistance to TAXOL / carboplatin
by: Jing Zhang, et al.
Published: (2021-09-01)

A cuproptosis-related signature predicts prognosis and indicates cross-talk with immunocyte in ovarian cancer
by: Bikang Yang, et al.
Published: (2024-05-01)

Utilizing Patient-Derived Epithelial Ovarian Cancer Tumor Organoids to Predict Carboplatin Resistance
by: Justin W. Gorski, et al.
Published: (2021-08-01)

Integrated analysis of the M2 macrophage-related signature associated with prognosis in ovarian cancer
by: Caijiao Peng, et al.
Published: (2022-08-01)

CircRAD23B promotes proliferation and carboplatin resistance in ovarian cancer cell lines and organoids
by: Hui Wang, et al.
Published: (2024-01-01)

ALKBH5 modulates macrophages polarization in tumor microenvironment of ovarian cancer
by: Yuanyuan An, et al.
Published: (2024-04-01)

Fast Leak-Proof, Intraumbilical, Single-Incision Laparoscopic Ovarian Cystectomy for Huge Ovarian Masses: “Hybrid Cystectomy and Reimplantation” Method
by: Sa Ra Lee
Published: (2021-07-01)

Human macrophage-engineered vesicles for utilization in ovarian cancer treatment
by: David Schweer, et al.
Published: (2023-01-01)

Optimizing Outcomes: Bevacizumab with Carboplatin and Paclitaxel in 5110 Ovarian Cancer Patients—A Systematic Review and Meta-Analysis
by: Yu Jin Kim, et al.
Published: (2024-08-01)

S100A10 silencing suppresses proliferation, migration and invasion of ovarian cancer cells and enhances sensitivity to carboplatin
by: Lingzhi Wang, et al.
Published: (2019-11-01)

The Role of Tumor-Associated Macrophages in the Progression and Chemoresistance of Ovarian Cancer
by: Marek Nowak, et al.
Published: (2020-05-01)

Carboplatin, paclitaxel, and pembrolizumab followed by pembrolizumab maintenance for primary treatment of incompletely resected epithelial ovarian cancer
by: Denise Uyar, et al.
Published: (2024-02-01)

Whole-exome sequencing and Drosophila modelling reveal mutated genes and pathways contributing to human ovarian failure
by: Ismael Henarejos-Castillo, et al.
Published: (2024-12-01)

Distinct genetic alterations occur in ovarian tumor cells selected for combined resistance to carboplatin and docetaxel
by: Armstrong Stephen R, et al.
Published: (2012-11-01)

Vascular normalization: reshaping the tumor microenvironment and augmenting antitumor immunity for ovarian cancer
by: Ping Yu, et al.
Published: (2023-10-01)

Combined Interval Cytoreductive Surgery and Carboplatin-Based Hyperthermic Intraperitoneal Chemotherapy in Advanced Primary High-Grade Serous Ovarian Cancer
by: Claudèle Brault, et al.
Published: (2023-12-01)

Primary high-grade serous ovarian cancer cells are sensitive to senescence induced by carboplatin and paclitaxel in vitro
by: Paweł Uruski, et al.
Published: (2021-10-01)

Incorporating genotype information in a precise prediction model for platinum sensitivity in epithelial ovarian cancer
by: Nai-Yi Du, et al.
Published: (2025-01-01)

Single-nucleus RNA Sequencing reveals the mechanism of cigarette smoke exposure on diminished ovarian reserve in mice
by: Fang Li, et al.
Published: (2022-10-01)

COM33 suppresses carboplatin-induced epithelial-mesenchymal transition via inhibition of Twist1 in ovarian cancer
by: Zhou Zhiyang, et al.
Published: (2022-12-01)